spacer
home > > summer 2011 > humanised studies
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

 
News and Press Releases

Cumulus Neuroscience Commences Clinical Studies of Digital Biomarker Platform in Degenerative Neurological Diseases

Belfast, UK – 25 May 2022. Cumulus Neuroscience, a global digital health company, announces the start of two validation trials – CNS-101 and CNS-102 – supported by a group of leading global pharma companies and Innovate UK. The studies will investigate the potential benefits of Cumulus’ integrated physiological and digital biomarker platform in quantifying cognitive decline over time in patients with dementia, across AD, ALS and FTD.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement